Περιεχόμενα
1:Introduction, Raffaele De Caterina, David J. Moliterno, and Steen Dalby Kristensen
Section 1: Pathophysiology of thrombosis
2:Arterial thrombosis: Pathophysiological background, Lina Badimon and Gemma Vilahur
3:Venous thrombosis and thromboembolism: Pathophysiological background, Marcello Di Nisio, Nicola Potere, Harry R. Buller, and Nick van Es
4:Thrombosis & thromboembolism in atrial fibrillation: Pathophysiological background, Peter Calvert, Nicola Tidbury, and Gregory Y. H. Lip
5:Thrombosis on foreign surfaces and devices, Tobias Geisler
Section 2: Clinical pharmacology of antithrombotic drugs
6:Aspirin, Carlo Patrono and Bianca Rocca
7:Platelet P2Y12 inhibitors, Manan Pareek and Deepak L. Bhatt
8:Dipyridamole, cilostazol, GP IIb/IIIa inhibitors, and PAR-1 antagonists, Luis Ortega-Paz and Dominick Angiolillo
9:Heparins, fondaparinux, hirudin, bivalirudin, argatroban and danaparoid, Renske Olie and Hugo ten Cate
10:Vitamin K antagonists, Freek W.A. Verheugt and Marc Brouwer
11:Dabigatran, Alex Benz and Stefan Hohnloser
12:Oral factor Xa (FXa) inhibitors, Lars C. Wallentin, Agneta Siegbahn, Peter Svensson, and Hakan Wallen
13:Forthcoming oral factor XIa and FXIIa inhibitors, James C. Fredenburgh and Jeffrey I. Weitz
14:Thrombolytic therapy and ancillary antithrombotic therapies, Peter R Sinnaeve and Frans Van de Werf
Section 3: Therapeutic strategies
15:Antithrombotic strategies in primary cardiovascular prevention, Raffaele De Caterina, Paul M Ridker, and Erica Michelotti
16:Antithrombotic strategies in patients undergoing elective percutaneous coronary interventions and in chronic coronary syndromes without interventions, Antonio Greco and Davide Capodanno
17:Antithrombotic therapy in ST-elevation acute myocardial infarction and non-ST elevation acute coronary syndromes, William A. E. Parker, Raffaele De Caterina, David J. Moliterno, Steen Dalby Kristensen and Robert F. Storey
18:Anti-thrombotic therapy for patients with prosthetic valves and during structural percutaneous interventions, Naoki Misumida, Mohamad Alkhouli, and David J. Moliterno
19:Antithrombotic therapies in ischaemic stroke, Hans Christoph Diener, Graeme J. Hankey, and John W. Eikelboom
20:Antithrombotic therapy in patients with patent foramen ovale (PFO), PFO closure, left ventricular mural thrombus, atrial thrombus, and catheter-related thrombosis, Jens Erik Nielsen-Kudsk, Kasper Korsholm, Asger Andersen, and Erik Lerkevang Grove
21:Atrial fibrillation: current and forthcoming antithrombotic therapies, Raffaele De Caterina and Rossella Marcucci
22:Venous thromboembolism: prophylaxis and treatment, Chaozer Er, Walter Ageno, and Ander Cohen
23:Biomarker-based risk stratification in cardiovascular disease, Lars C. Wallentin, Ziad Hijazi, Gorav Bartra, and Johan Lindbäck
Section 4: Special situations
24:Antithrombotic therapies in inherited or acquired thrombophilia, Vittorio Pengo and Gentian Denas
25:Prevention and treatment of bleeding related to antithrombotic drug treatment, Roxana Mehran, Alessandro Spirito, George Dangas, and David Cao
26:Management of patients treated with antithrombotic drugs undergoing surgery, Michael Maeng, Steen Dalby Kristensen, and Jolanta M. Siller-Matula
27:Antithrombotic therapy in patients with atrial fibrillation and recent coronary stenting, with or without an acute coronary syndrome, Alexander C Fanaroff, Renato D Lopes, John H Alexander
28:Prevention and treatment of venous and arterial thrombosis in patients with specific conditions: diabetes, renal insufficiency, thrombophilia and pregnancy, Stefan Agewall, Vanessa Roldán, and Francisco Marín
29:Antithrombotic agents and drug-drug interactions, Steven P. Dunn, Craig J. Beavers, and David J. Moliterno
30:Personalised antithrombotic therapy: Measuring individual variation and monitoring, Jur ten Berg, Dirk Sibbning, Wout W.A. van den Broek, and Konstantinos D. Rizas
31:Drug development, clinical trials, and regulatory requirements, Serge Korjian, Yazan Daaboul, and C. Michael Gibson
